
There is not a standardized definition of rapidly worsening Multiple zzso zzso zzso we have designed under this term patients having a very active zzso zzso having more than 2 relapses within the last 12 zzso or rapid progression of handicap (more than 2 points zzso progression within the last 12 zzso The design of most previous studies using zzso zzso zzso do not fulfill criteria to draw final conclusions as to the efficacy of these drugs as an zzso agent in Multiple zzso zzso During the last five years, efficacy of zzso and zzso agents was provided by some zzso zzso control clinical zzso among the zzso zzso deserves special consideration as there were three controlled trials in Europe during the two last years that demonstrated strong efficacy both on clinical and zzso zzso Due to its potentially zzso related to total cumulative dose, zzso should presently only be used in selected patients with a very high zzso rate and incomplete zzso or in those who do not respond to INF beta zzso The zzso agents zzso beta zzso or zzso zzso 1) demonstrated a significant effect on the reduction of zzso rate (about 30 zzso cent zzso on progression of handicap and on zzso In secondary progressive zzso an effect on progression is demonstrated only on patients still having zzso No trial devoted to worsening patients as defined above have been yet designed with zzso zzso 

